Abstract:Background Immunomodulatory therapy has been extensively studied in randomized clinical trials for the treatment of patients hospitalized for COVID-19 with inconsistent findings. Guideline committees, reviewing the same clinical trial data, have generated different recommendations for immunomodulatory therapy. Objectives We hypothesize that trial design differences, specifically whether the study utilized an open-label or placebo-controlled design, accounted for the inconsistent mortality effects reported in clinical trials of immunomodulator therapies for COVID-19. Sources We reviewed COVID-19 treatment guidelines (WHO, IDSA and NIH) and identified the meta-analyses associated with glucocorticoids, IL-6 inhibitors, JAK kinase inhibitors, and complement C5a inhibitors that were available to the guideline authors at the time recommendations were either made or updated. Content We identified a meta-analysis for each of the immunomodulator classes that are included in current COVID-19 treatment guidelines: glucocorticoids (JAMA. 2021;326(6):499-518 cited 419), IL-6 antagonists (JAMA. 2021;326(6):499-518 cited 419), JAK inhibitors (Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209 cited 34) and complement C5a inhibitors (Expert Review of Anti-infective Therapy, 21:1, 77-86 cited 1). Using the same RCTs, we evaluated the 4 meta-analyses accounting for trial design: placebo-controlled or open-label. Glucocorticoids (RR 0.91 [95% CI, 0.49-1.69]), IL-6 inhibitors sarilumab (RR 1.17 [95% CI, 0.96-01.43]) and tocilizumab (RR 0.95 [95% CI, 0.76-1.19]) did not reduce mortality in placebo-controlled trials, whereas baricitinib did confer a large survival benefit (RR 0.65, [95% CI 0.52-0.81]). The complement C5a inhibitor, vilobelimab, also reduced mortality in a single placebo-controlled trial (RR 0.76 [95% CI, 0.57-1.0]). Implications Placebo-controlled trial evidence indicates that baricitinib should be the first choice immunomodulator for patients hospitalized for COVID-19 who require any form of oxygen support—low or high-flow oxygen, non-invasive or invasive ventilation. Vilobelimab warrants study in a large placebo-controlled trial. Treatment guidelines for future pandemics should prioritize the results of placebo-controlled trials.

What are the clinical and research lessons learned from immunomodulators and other therapies during the COVID-19 pandemic?

Lessons Learned From Clinical Trials of Immunotherapeutics for COVID‐19

Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions

Therapeutic strategies for COVID-19: progress and lessons learned

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations

Promising Immunotherapies Against COVID‐19

Covid-19: Imbalanced Immune Responses And Potential Immunotherapies

A brief review on the lessons learned from COVID-19 on drug discovery and research

A guide to immunotherapy for COVID-19

What the SARS-CoV-2 Pandemic Has Taught Us About Immunosuppression, Vaccinations, and Immune Dysregulation: The Rheumatology Experience

Immune-mediated approaches against COVID-19

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Immunotherapeutic approaches to curtail COVID-19

Therapeutic advances in COVID-19

COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs

Recent advances in vaccine and immunotherapy for COVID-19

SEVERE CORONAVIRUS DISEASE 2019: FROM PATHOGENESIS TO THERAPY

Choosing immunomodulating therapies for the treatment of COVID-19: Recommendations based on placebo-controlled trial evidence

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.

Recent advances in immunotherapies against infectious diseases